Business
UK Government to support lipid systems expansion
UK Government to support lipid systems expansion.
About this update from Croda International Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8240G\n Croda International PLC\n 31 March 2022\n \n \n \n \n Press Release \n \n \n \n \n \n 31 March 2022\n \n \n \n \n \n UK Government to support expansion of Croda's lipid systems manufacturing facility\n \n \n \n \n \n Croda International Plc ('Croda' or 'the company'), the company that uses smart science to create high performance ingredients and solutions that improve lives, announces that it has been awarded a £15.9 million grant by the UK Government to expand its manufacturing facility in Leek, Staffordshire. The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines. \n \n \n \n \n \n Croda will also invest £15.9m in the expansion. This is included within the company's existing capital expenditure programme outlined in the recent annual results, which will see investment in the coming years in assets and capabilities to support pharmaceutical customers with leading solutions for the delivery and enhancement of novel therapeutic drugs, vaccines and gene therapies. This forms part of Croda's evolution to a 'pure play' Consumer Care and Life Sciences business. \n \n \n \n \n \n The expansion will include building a state-of-the-art lipid system synthesis facility and enhancing innovation and analytical laboratory capabilities at Leek. The site specialises in the production of lipids, that are currently used in a number of COVID-19 mRNA vaccines, as well as other Croda health care technologies such as speciality excipients. The investment will expand the range of speciality lipids produced at the site and add significant additional production capacity. \n \n \n \n \n \n Lipid systems offer significant potential beyond COVID-19 as the preferred delivery system for gene editing and mRNA therapeutics. The range of applications for lipid systems is expected to expand rapidly as this exciting platform develops through clinical trials to commercial launches of new RNA-based applications, such as flu vaccines and cancer treatments. The investment will also materially strengthen the UK's supply chain in this critical area and ensure that the country is well prepared in the event of future health emergencies.\n \n \n \n \n \n The Secretary of S...